Column-switching high-performance liquid chromatographic determination of a 2-pyridinone-based human immunodeficiency virus type 1 (HIV-1)-specific reverse transcriptase inhibitor in human plasma.
A method for the determination of a 2-pyridinone-based specific HIV-1 reverse transcriptase inhibitor in human plasma is described. Plasma samples are extracted using phenyl solid phase extraction columns. The extract is analyzed via HPLC using a column-switching system to remove interferences from late-eluting endogenous components. Detection is based on UV absorbance at 314 nm. The assay was linear in the concentration range of 10-500 ng/ml, when 1-ml aliquots of plasma were extracted. The mean precision of the assay, expressed as the coefficient of variation, was 3.8%. The assay has been validated and utilized to support human pharmacokinetic studies.
Woolf
E J
EJ
Merck Sharp and Dohme Research Laboratories, Department of Drug Metabolism, West Point, Pennsylvania 19486.
Matuszewski
B K
BK
D001583:Benzoxazoles / Q000097:blood / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D054303:HIV Reverse Transcriptase; D015497:HIV-1 / Q000201:enzymology*; D006801:Humans; D011728:Pyridones / Q000097:blood / Q000494:pharmacology*; D011786:Quality Control; D018894:Reverse Transcriptase Inhibitors; D013056:Spectrophotometry, Ultraviolet
D001583:Benzoxazoles; D011728:Pyridones; D018894:Reverse Transcriptase Inhibitors; C076250:L 696229; D054303:HIV Reverse Transcriptase